Literature DB >> 31730260

Epidemiology of multimorbidity in Iran: An investigation of a large pharmacy claims database.

Reza Ebrahimoghli1, Ali Janati1, Homayoun Sadeghi-Bazargani2, Hadi Hamishehkar3, Samad Ghaffari4, Zohreh Sanaat5, Mostafa Farahbakhsh6, Mehdi Farhoudi7, Atefeh Khalili-Azimi1.   

Abstract

PURPOSE: Multimorbidity (MM) (presence of more than one chronic condition within a same patient) imposes a heavy burden on patients and health care systems. In contrast to high-income countries, the epidemiology of this phenomenon is unclear in low- and middle-income countries, particularly among Iranian population.
METHODS: This was a retrospective cohort study using Iranian Health Insurance Organization claims database. A framework was developed for identifying a set of 18 chronic conditions from the pharmacy claims data in Iran. All 2013 outpatient utilizers (aged 18 years or older) were included. Data were analyzed according to number of chronic conditions, gender, and age. The association between MM and utilizations of health services was examined for 2013 to 2016.
RESULTS: In total, 481 733 people were included. Cardiovascular diseases (including hypertension) (19.1%), depression/anxiety/sleep disorders (13.7%), and acid-related disorders (10.3%) were the three most prevalent conditions. MM was present in 21.1%. Although prevalence of MM is higher in older age groups and was present in 40% of individuals aged 65 and older, the absolute number of multimorbid patients was higher in those younger than 65 years (66 271 vs 35 386). MM was more prevalent among women (22.1%) compared with men (19.5). After multivariate adjustment for age group and sex, each additional chronic condition was associated with an increase of 2.23 physician visits, 2.86 drugs dispensed, 2.32 laboratory tests, and 1.6 medical imaging.
CONCLUSIONS: Our findings challenge the current single-disease-based assumption implicit in Iranian health care system. To take account of MM, complementary strategies should be designed and implement in health care system.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  claims database; low- and middle-income countries; multimorbidity; noncommunicable diseases; pharmacoepidemiology

Year:  2019        PMID: 31730260     DOI: 10.1002/pds.4925

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  5 in total

1.  Incremental Healthcare Resource Utilization and Expenditures Associated with Cardiovascular Diseases in Patients with Diabetes: A Cross-Sectional Study.

Authors:  Reza Ebrahimoghli; Ali Janati; Homayoun Sadeghi-Bazargani; Hadi Hamishehkar; Atefeh Khalili-Azimi
Journal:  Iran J Med Sci       Date:  2022-01

2.  Multimorbidity and associations with clinical outcomes in a middle-aged population in Iran: a longitudinal cohort study.

Authors:  Maria Lisa Odland; Samiha Ismail; Sadaf G Sepanlou; Hossein Poustchi; Alireza Sadjadi; Akram Pourshams; Tom Marshall; Miles D Witham; Reza Malekzadeh; Justine I Davies
Journal:  BMJ Glob Health       Date:  2022-05

3.  Prevalence and Predicting Risk Factors of Polypharmacy in Azar Cohort Population.

Authors:  Afshin Gharekhani; Mohammadhossein Somi; Alireza Ostadrahimi; Ayda Hatefi; Arash Haji Kamanaj; Sina Hassannezhad; Elnaz Faramarzi
Journal:  Iran J Pharm Res       Date:  2022-05-08       Impact factor: 1.962

4.  Proposed Model of Management for Patients with Multi-Morbidity in Iranian Hospitals.

Authors:  Firooz Toofan; Seyed Mojtaba Hosseini; Khalil Alimohammadzadeh; Mehrnoosh Jafari; Mohammadkarim Bahadori
Journal:  Med J Islam Repub Iran       Date:  2022-04-14

5.  Multimorbidity of non-communicable diseases in low-income and middle-income countries: a systematic review and meta-analysis.

Authors:  Ogechukwu Augustina Asogwa; Daniel Boateng; Anna Marzà-Florensa; Sanne Peters; Naomi Levitt; Josefien van Olmen; Kerstin Klipstein-Grobusch
Journal:  BMJ Open       Date:  2022-01-21       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.